The PENTO Protocol in Medication-related Osteonecrosis of the Jaw
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
Medication-related osteonecrosis of the jaw (MRONJ) occurs after taking bisphosphonates or
targeted therapies. It leads to a significant decrease in quality of life with pain, eating
and chewing disorders, and malnutrition. Current treatments are only partially effective.
PENTO (pentoxifylline and tocopherol) has been shown to be effective in maxillary
osteoradionecrosis. The objective of this study is to evaluate the proportion of bone
recovery in patients receiving PENTO in MRONJ at 12 months.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Limoges
Treatments:
alpha-Tocopherol Pentoxifylline Tocopherols Tocotrienols Vitamin E